Acceleron Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Acceleron Pharma's estimated annual revenue is currently $17.3M per year.
- Acceleron Pharma received $264.5M in venture funding in January 2019.
- Acceleron Pharma's estimated revenue per employee is $201,000
- Acceleron Pharma's total funding is $987M.
Employee Data
- Acceleron Pharma has 86 Employees.
- Acceleron Pharma grew their employee count by -20% last year.
Acceleron Pharma's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Associate Director, CQA | Reveal Email/Phone |
2 | Area Director - East, U.S. | Reveal Email/Phone |
3 | Senior Manager, Pharmacovigilance Operations | Reveal Email/Phone |
4 | Senior Clinical Trial Manager | Reveal Email/Phone |
5 | Manager, Cell Culture | Reveal Email/Phone |
6 | Scientist I, Bioanalysis & Pharmacokinetics | Reveal Email/Phone |
7 | Senior Hematology/Oncology Specialist | Reveal Email/Phone |
8 | Sr RA | Reveal Email/Phone |
9 | Senior Hematology Oncology Specialist | Reveal Email/Phone |
10 | Senior Hematology Account Executive | Reveal Email/Phone |
Acceleron Pharma Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $413.3M | 324 | 0% | $634M | N/A |
#2 | $47.8M | 238 | 0% | N/A | N/A |
#3 | $2.4M | 12 | -52% | N/A | N/A |
#4 | $25.7M | 128 | 39% | N/A | N/A |
#5 | $12.9M | 64 | 129% | N/A | N/A |
#6 | $23.9M | 119 | 8% | $113M | N/A |
#7 | $0.3M | 3 | 0% | N/A | N/A |
#8 | $10.3M | 51 | -14% | N/A | N/A |
#9 | $1.8M | 367 | -4% | $538M | N/A |
#10 | $50M | 249 | 3% | N/A | N/A |
What Is Acceleron Pharma?
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2 pulmonary program with sotatercept in pulmonary arterial hypertension.
keywords:Biotechnology,Cleantech,E-Commerce,Healthcare,Pharmaceuticals,Wind Power
$987M
Total Funding
86
Number of Employees
$17.3M
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Acceleron Pharma News
Acceleron Pharma Inc, Addmedica SAS, Angiocrine Bioscience Inc, Annexin Pharmaceuticals AB, ArQule Inc, Bio Products Laboratory Ltd,...
In November 2021, Merck completed its acquisition of Acceleron Pharma for about $11.5 billion. As is often the case with mergers and...
On Tuesday, March 15, Merck issued a Worker Adjustment and Retraining Notification Act (WARN) notice to 143 legacy employees of Acceleron Pharma who will be...
The company’s previous fund was $269 million. Some of its more successful exits during this biotech boom have been the IPOs of Receptos, Agios Pharmaceuticals, Tetraphase Pharmaceuticals and Acceleron Pharma. Other notable companies that remain under its wing include mRNA therapeutics biotech Mo ...
I won’t get into Aratana Therapeutics (Nasdaq: PETX) because the biopharmaceutical company develops treatments for animals. Acceleron Pharma: (Nasdaq: XLRN) raised $96.7 million after it priced at the high end of its share price range. The company develops treatments based on Transforming Growt ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $18.1M | 86 | 8% | N/A |
#2 | $10.5M | 86 | -2% | $202M |
#3 | $8.8M | 86 | 5% | N/A |
#4 | N/A | 86 | -12% | N/A |
#5 | $7.5M | 86 | 121% | N/A |
Acceleron Pharma Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2004-02-16 | $25.0M | 1st | Polaris Venture Partners | Article |
| 2006-01-06 | $8.0M | Undisclosed | Hercules Technology Growth Cap | Article |
| 2006-08-03 | $30.0M | B | OrbiMed Advisors | Article |
| 2007-10-31 | $31.0M | C | Bessemer Venture Partners | Article |
| 2011-12-27 | $30.0M | Undisclosed | Celgene | Article |
| 2014-01-22 | $100.0M | Undisclosed | Citigroup | Article |
| 2017-09-22 | $230.0M | Undisclosed | J.P. Morgan Securities LLC | Article |
| 2019-01-17 | $264.5M | Undisclosed | Citigroup | Article |